Citations

Clear

2292 citation(s) found for "Singh, R".

PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Weiss, J., Chintakuntlawar, Ashish, Worden, Francis P., Mehra, Ranee , Kang, Hyunseok , Zinner, Ralph G., Arnold, Susanne M. , Bhateja, Priyanka, Harrington, Kevin, Gupta, Shilpi, Zhao, Yujie, Pham, Dahn C., Najeeb, Sidra, Kaur, Varinder, Sukari, Ammar, Giri, Anshu , Panella, Timothy J., Grewal, Jaspreet, Galligan, Barbara, Nadler, Eric, Grant, Cliona, Arteta-Bulos, Rafael, Schaaf, David, Price, Katharine A., Kang, Hyunseok , Weiss, Jared, Kaczmar, John M. , Zinner, Ralph , Harrington, Kevin J. , Kaur, Varinder , Sukari, Ammar , Panella, Timothy, Grewal, Jaspreet Singh , Galligan, Barbara Marie, Nadler, Eric , Noble, David J. , Schaaf, David

Mayo Clinic

JAMA Oncology | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.3492 | PMID 42752531 Get It

Importance The incidence of human papillomavirus type 16 (HPV16–positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. Objective To determine the efficacy and safety of a therapeutic HPV16-targeted immunotherapy, PDS0101, in combination with pembrolizumab in participants with HPV16-positive R/M HNSCC, with separate evaluation of immune checkpoint inhibitor (ICI)–naive and ICI-resistant cohorts. Design, Setting, and Participants VERSATILE-002 was a phase 2, open-label, multicenter nonrandomized clinical trial conducted at 26 oncology centers from March 29, 2021, to May 15, 2025, across the US, UK, and Ireland using the Simon 2-stage optimal design. Efficacy analyses were performed on modified intent-to-treat (mITT) population; safety analyses included all participants who received 1 or more doses. Eighty-eight participants with histologically confirmed R/M HPV16-positive HNSCC were enrolled, of whom 87 (98.9%) received treatment and composed the safety population. Seventy five (85.2%) were in the mITT population used for efficacy analyses, of whom 53 (70.7%) were ICI-naive with a programmed cell death ligand 1 combined positive score of 1 or greater and 22 (29.3%) were ICI-resistant. Exposures Pembrolizumab (200 mg, intravenously, every 3 weeks for up to 35 cycles) plus subcutaneous PDS0101 (5 scheduled doses per protocol). Main Outcomes and Measures The primary end point was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors , version 1.1, by a masked independent central reviewer. Secondary end points included progression-free survival (PFS), median overall survival (mOS), and safety, with exploratory end points of duration of response, disease control rate, and response rates by programmed cell death ligand 1 status. Results Of the 75 patients in the mITT population, the mean (SD) age was 64.0 (8.3) years; 4 individuals (5%) were female and 71 (95%) were male; and 2 individuals (3%) were Asian, 1 (1%) was Black, 5 (7%) were Hispanic, and 71 (95%) were White. Among 53 ICI-naive participants in the mITT cohort, ORR by the central reviewer was 34.0%, median PFS was 5.3 months (95% CI, 2.10-9.00), and mOS was 39.3 months (95% CI, 23.90 to not evaluable). Among 22 ICI-resistant patients in the mITT cohort, no objective responses were observed and the primary end point (ORR by central reviewer) was not met, but mOS was 14.8 months (95% CI, 8.50-26.00). The treatment was well tolerated, with 13.8% experiencing grade 3 or higher treatment-related adverse events. Conclusions and Relevance The results of this nonrandomized clinical trial suggest that PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, with favorable safety, response rates, and survival outcomes. The findings support further evaluation in a first-line setting. Trial Registration ClinicalTrials.gov Identifier: NCT04260126
Distinct and shared multimodal neuroimaging patterns in clinical frontotemporal dementia syndromes
Sintini, Irene , Ali, Farwa , Duffy, Joseph R. , Clark, Heather M, Meade, Gabriela, Dickson, Dennis W. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar , Duffy, Joseph R , Meade, Gabriela F, Dickson, Dennis W , Josephs, Keith A , Whitwell, Jennifer , Singh, Neha Atulkumar , Clark, Heather M. , Utianski, Rene L. , Meade, Gabriela , Machulda, Mary M. , Satoh, Ryota

Mayo Clinic

Brain Communications | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/braincomms/fcag341 | PMID 42756560 Get It

Abstract Clinical syndromes of frontotemporal dementia present both distinct and overlapping neuroimaging abnormalities and, consequently, domains of impairment. The aim of this study was to determine how well covariance patterns from multiple neuroimaging modalities discriminate across clinical frontotemporal dementia syndromes. Four-hundred participants with a clinical frontotemporal dementia diagnosis, including behavioral variant of frontotemporal dementia, semantic variant of primary progressive aphasia, right temporal variant of frontotemporal dementia, primary progressive aphasia, apraxia of speech with agrammatic aphasia, primary progressive apraxia of speech, progressive supranuclear palsy and corticobasal syndrome, and 109 cognitively unimpaired participants underwent extensive neurological and neuropsychological assessments, structural MRI, flortaucipir-PET for tau and [18F] fluorodeoxyglucose-PET. Multimodal imaging covariance was investigated at the voxel-level using principal component analysis after adjusting for age and sex effects. Linear regression models were fit to investigate the relationship between principal components and clinical scores. Multinomial logistic regression models investigated the ability of imaging principal components to discriminate across syndromes. The first principal component, which describes the largest source of variability in the data, was a pattern of widespread cortical atrophy (21% variability explained) and of frontoparietal and temporal hypometabolism (21%): scores were lowest in behavioral variant of frontotemporal dementia and correlated with general cognitive impairment. On tau-PET, the first principal component (43% variability) was not significantly different among syndromes and captured a widespread cortical tau uptake, with a focus on the temporal lobe. In all three modalities, the second principal component captured temporal lobe imaging abnormalities, contrasting the motor and semantic clinical syndromes. Subsequent components described smaller variability. On cross-validation, the classifiers based on principal components from MRI (multiclass area under the receiver operating characteristic: 0.76) and [18F]fluorodeoxyglucose-PET (0.79) outperformed tau-PET (0.71), while combining all three modalities did not significantly improve the classifier performance. On cross-validation, the sensitivity of the image-based classifiers was heterogeneous across syndromes and modalities, with highest values for progressive supranuclear palsy and semantic variant of primary progressive aphasia and lowest for primary progressive aphasia and corticobasal syndrome. Our study found that the covariance components of structural and molecular neuroimaging underlying frontotemporal dementia clinical syndromes exist both as a continuum and with syndrome-specific patterns. More than one imaging model was able to correctly classify several frontotemporal dementia clinical syndromes with good specificity and sensitivity, highlighting the value of imaging in aiding patient diagnosis.
The Headache Innovation Challenge: An outgrowth of the AHS/NINDS Headache research priorities
Vallimont, Jenn , Singh, Rashmi B. Halker , Charleston, Larry , Gelfand, Amy A. , Halker Singh, Rashmi B , Charleston, Larry , Gelfand, Amy A

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/head.70230 | PMID 42706866 Get It

Laparoscopic Cholecystectomy Is a Time-Sensitive Operation: National Outcomes Associated With Delayed Surgery
Bhatt, Himani , Orduno Villa, Nancy , Kumar, Jayant, Vakil, Deep , Singh, Sahajpreet, Young, Samantha, Curcio, Gary, Rosenthal, Andrew , Parreco, Joshua, Curcio, Gary, Rosenthal, Andrew, Parreco, Joshua P.

Mayo Clinic

The American Surgeon™ | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261486928 | PMID 42709057 Get It

Background Competition for urgent and emergent operating-room access is a significant challenge in many hospitals. Evidence-based benchmarks for early intervention are well established for emergencies like acute appendicitis or hip fracture. In contrast, laparoscopic cholecystectomy for acute cholecystitis or symptomatic cholelithiasis is often delayed. The purpose of this study was to evaluate the clinical and economic impact of delays in laparoscopic cholecystectomy across the US. Methods The Nationwide Readmissions Database was queried for patients aged ≥18 years admitted between 2021 and 2022 undergoing urgent or emergent laparoscopic cholecystectomy. Patients were stratified based on operative timing (<3 vs ≥ 3 days). The primary outcome was 30-day readmission. Secondary outcomes included VTE, SSI, and total cost. Propensity score matching (1:1) was performed using 46 covariates. Linear regression assessed the cost associated with each additional hospital day prior to surgery, with a subgroup analysis of safety-net hospitals. Results Among 136,893 patients, 24,496 (17.9%) experienced delayed laparoscopic cholecystectomy. After matching (n = 48,992), delays were associated with increased odds of readmission (9.5%; OR 1.22 [1.15-1.29], P < 0.001) and VTE (1.5%; OR 1.51 [1.30-1.77], P < 0.001). SSI (0.2%) was not significantly different. The mean total cost was $25,957 ± $21,609 for delayed patients vs $20,784 ± $20,027 for early surgery. Linear regression revealed an incremental cost of $1,695 per additional hospital day prior to surgery, rising to $2071 per day in safety-net hospitals ( P < 0.001). Discussion Delays in laparoscopic cholecystectomy have significant clinical and economic impacts, underscoring the urgent need for national benchmarks to standardize operative timing and reduce disparities for patients in safety-net hospitals.
Invasive network neuromodulation for insular epilepsy: A three‐center retrospective study
Singh, Raunak, Gregg, Nicholas M. , Starnes, Keith , Osman, Gamaleldin , Gompel, Jamie J. Van , Miller, Kai J. , Tatum, William O. , Crepeau, Amy, Worrell, Gregory A. , Alcalá-Zermeño, Juan Luis , Singh, Raunak , Starnes, Donnie Keith , Van Gompel, Jamie J , Lundstrom, Brian Nils , Worrell, Gregory A , Gregg, Nicholas M , Osman, Gamaleldin , Crepeau, Amy Z. , Lundstrom, Brian N.

Mayo Clinic

Epilepsia | September 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70479 | PMID 42704242 Get It

Abstract To characterize invasive neuromodulation for insular drug‐resistant epilepsy, we retrospectively evaluated 22 patients treated with responsive neurostimulation (RNS; n = 14) or chronic subthreshold stimulation (CSS; n = 8). Stereoelectroencephalography was performed in 20 cases (91%). Median baseline seizure frequency was 10.5/month. Forty‐one percent had prior epilepsy surgery. At year 3, median seizure reduction (MSR) was 83% ( p = .01, Wilcoxon signed‐rank test), with a responder rate (RR) of 77%; MSR was 92% for CSS and 75% for RNS. There were no significant differences in MSR ( p ≥ .4) or RR ( p > .9) when comparing RNS versus CSS. Three patients achieved seizure freedom by year 3. Patients undergoing combined insular–thalamic stimulation ( n = 5) demonstrated an MSR of 84%, 86%, and 88% at 1, 2, and 3 years; seizure reduction in thalamocortical versus cortical‐only stimulation was not different ( p ≥ .1). Parasagittal lead trajectories achieved closer insular proximity than transopercular trajectories ( p < .0001, Mann–Whitney U ‐test). Median charge density at last follow‐up was 1.3 μC/cm 2 . There were no acute surgical complications and all stimulation‐related side effects resolved with programming adjustments. This study expands the limited literature on insular neuromodulation by demonstrating effectiveness of RNS and CSS, suggesting potential benefit from combined thalamocortical targeting, and defining parasagittal trajectories as a surgical approach for optimal lead proximity.
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial
Singh, Balwinder , MahmoudianDehkordi, Siamak , Vande Voort, Jennifer L., Parikh, Sagar V., Achtyes, Eric D. , Bobo, William V. , Greden, John F., Scaini, Giselli, Tye, Susannah J. , Frye, Mark A. , Kaddurah-Daouk, Rima, V Bobo, William , Tye, Susannah J , Singh, Balwinder , Voort, Jennifer L. Vande , Parikh, Sagar V. , Goes, Fernando , Scaini, Giselli , Kaddurah‐Daouk, Rima

Mayo Clinic

The World Journal of Biological Psychiatry | September 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-15

10.1080/15622975.2026.2724510 | PMID 42702010 Get It

From Housing to Hotspots: Integrating a Housing-Based Measure of Individual Socioeconomic Status with Geospatial Analysis to Target Colorectal Cancer Screening in Rural Communities
Yao, Rebecca , Beenken, Madison, Watson, Dave , Wheeler, Philip H., Finch, Mike, Kelleher, Dan , Anil, Gokhan , Anderson, Trent, Madden, Kathy A., Okuno, Scott H. , Odedina, Folakemi T., Park, Eunice , Dugani, Sagar B., Sosso, Jessica , Sabarish, Shivani , Singh, Gurpreet, Lugo-Fagundo, Nahyr, Kim, W. Ray, Walker-Mcgill, Cheryl L., Juhn, Young J. , Lynch, Brian , Wi, Chung‐Il , Madden, Kathy A., Westfall, Erin , Sharma, Pravesh , Dugani, Sagar B. , Foss, Randy , Hidaka, Brandon H. , Singh, Gurpreet, Howick V, James F , Calvin, Andrew D. , Walker-McGill, Cheryl Lynn, Rennert, Lior , Cerhan, James R. , Beenken, Madison J, Kelleher, Dan P., Westfall, Erin C, Park, Eunice Y., Sharma, Pravesh , Foss, Randy M, Sosso, Jessica L

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.28.26361444 | PMID 42922856 Get It

ABSTRACT Purpose This study assesses the association between colorectal cancer (CRC) screening and a validated, housing-based measure of individual-level socioeconomic status (SES, called HOUSES hereafter) within rural communities and determines whether HOUSES-integrated geospatial analysis can be used to tailor interventions. Methods We used CRC screening data from a subset of Mayo Clinic Midwest patients living in cities without ready access to routine care in the Mayo Clinic Health System in 2019 to represent rural communities. At the individual level, we assessed the association between CRC screening rates and the HOUSES index, adjusting for age, sex, race/ethnicity, comorbidity, distance from home address to clinic, and area deprivation index, using a multilevel mixed-effects logistic regression model. Additionally, we conducted geospatial analysis to examine the correlation between hotspots of 1) lower CRC screening rates and 2) lower SES of the subject population (HOUSES quartile 1). Findings Among 34,489 individuals (median age 64.0 years, 52.4% female), those with the lowest SES (HOUSES Q1) had 37% lower odds of being CRC screening adherent than those with the highest SES (HOUSES Q4) (adj. OR [95% CI]: 0.63 [0.58-0.69]). In the 14 identified HOUSES Q1 hotspots, there was a significant correlation in counts of HOUSES Q1 and low CRC screening (correlation coefficient=0.81). Conclusion Lower SES was significantly associated with lower CRC screening among rural populations. HOUSES-enabled geospatial analysis identified geographic hotspots with lower CRC screening rates for targeted interventions to address disparities in CRC screening in rural communities. HOUSES may be a useful digital tool for cancer preventive care and research.
Enterochromaffin cells as a cellular integration hub for cooperative microbial signaling to modulate gut serotonin and motility
Xiao, Yang , Till, Lisa , Gupta, Yash, Mercado‐Perez, Arnaldo , Bhagwate, Aditya V., Bellampalli, Shreya S. , Stark, Alejandro , Sekhon, Prabhjot K., Singh, Vaidhvi , Tienter, Dennis, Thompson, Michael A. , Kossick, Kimberlee , Krueger, Eugene W., Kalari, Krishna R., Hawkins, Kaitlyn R., Edwards, Brian S. , Alcaino, Constanza, Guo, Chun‐Jun , Druliner, Brooke R., Ördög, Tamás , Farrugia, Gianrico , Kashyap, Purna , Louwies, Tijs, Mars, Ruben A T, Mercado-Perez, Arnaldo, Bellampalli, Shreya S , Stark Quiroz, Alejandro , Liu, Rongfang , Thompson, Michael A , Kossick, Kimberlee , Lee, Jeong-Heon , van der Es, Daan , Willett, Julia L E , Wongkrasant, Preedajit , Prakash, Y S , Ordog, Tamas , Farrugia, Gianrico , Beyder, Arthur , Smith-Edwards, Kristen M , Kashyap, Purna C , Louwies, Tijs , Mars, Ruben A. , Gupta, Yash , Bhagwate, Aditya , Sekhon, Prabhjot Kaur , Heitman, Laura H. , Krueger, Eugene W. , Lee, Jeong‐Heon , Alcaino, Constanza , Willett, Julia L. E. , Wongkrasant, Preedajit , Prakash, Y. S. , Druliner, Brooke R. , Beyder, Arthur

Mayo Clinic

Proceedings of the National Academy of Sciences | August 24, 2026 | Volume: 123 | Issue: 35 | Pages: No page available

10.1073/pnas.2533336123 | PMID 42636369 Get It

The intestinal epithelium is exposed to diverse combinations of microbiota-derived compounds; however, the mechanisms by which the host integrates these signals remain poorly defined. Studying two highly abundant microbial metabolites, we identified the purine metabolite hypoxanthine as an effector metabolite that directly drives signaling and the short-chain fatty acid butyrate as a regulatory metabolite that conditions host responsiveness. Specifically, hypoxanthine activates the adenosine A1 receptor–TRPC4 axis in enterochromaffin (EC) cells, triggering calcium influx and serotonin release resulting in accelerated gastrointestinal transit locally and increased platelet activation systemically. In contrast, butyrate epigenetically upregulates specific G protein–coupled receptors and ion channels to enhance response to hypoxanthine and the neurotransmitters norepinephrine and dopamine. These findings define a cooperative signaling framework and highlight the role of EC cells as a distinct epithelial signaling hub that senses and integrates microbial metabolite signals to drive physiological responses. Our findings provide a mechanistic foundation for therapeutic strategies that leverage combinatorial microbial signaling.
OA08.2. Impact of GLP1 Receptor Agonists on Progression of Non Dysplastic Barrett’s Esophagus: A Large Propensity Matched Cohort Study
Mann, Russaal Singh, Sachdeva, Karan, Dhaliwal, Lovekirat , Larson, Stefanie, Iyer, Prasad G. , Sachdeva, Karan

Mayo Clinic

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.054 Get It

Abstract Topic Esophageal Cancer: Barrett‘s Esophagus: High-Grade Dysplasia and Early Invasive Cancer Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying and are linked to increased gastroesophageal reflux, a recognized risk factor for Barrett’s esophagus (BE) progression to esophageal cancer (EC). Extended use of GLP-1 RAs facilitates weight loss, mitigating reflux, possibly offering a protective effect against EC. This large retrospective study aimed to assess the association between GLP-1 use with the development of dysplastic Barrett’s esophagus (BE) and EC in patients with non-dysplastic BE (NDBE). Methods We used ICD and CPT codes within the TriNetX (a large multicenter claims based) database to identify NDBE patients. The cohort was then categorized as GLP-1 users vs. non-users based on ATC code A10BJ. A 1:1 propensity matched analysis was performed with balancing of confounders (Table 1). Primary outcomes included incidence of dysplastic BE and EC. Time to event analyses were performed. Results A total of 4,534 patients were identified in the GLP-1 cohort and 55,621 in the non-GLP-1 cohort. After 1:1 matching, 4,530 patients were included in each cohort. Mean follow-up was 3.57 years in GLP-1 cohort and 3.30 years in non-GLP-1 cohort. Incidence of dysplastic BE/EC in the GLP 1 cohort was 1.24% (N=56) compared to 0.54% (N=24) in non-GLP 1 cohort. GLP-1 users demonstrated significantly higher risk of developing dysplastic BE/EC compared to non-users (RR: 2.30; 95% CI: 1.47–3.70, P = 0.0004. The cumulative incidence of dysplastic BE/EC was higher among GLP-1 cohort at 3 and 5 years—0.90 %, and 1.11%, respectively—compared to 0.47%, and 0.49 % in the non-GLP-1 group. Conclusion Our findings indicate that GLP-1 therapy was associated with an increased risk of progression to dysplastic BE/EC in patients with non-dysplastic BE. Further prospective studies are warranted to validate these results.
Variability in recommending epilepsy surgery across Level IV epilepsy centers in the United States
Caraway, Avery R. , McNamara, Nancy A. , Knox, Andrew , Samanta, Debopam , Wolf, Steven M. , Novotny, Edward J., Ostendorf, Adam P. , Eschbach, Krista , Depositario‐Cabacar, Dewi F. , Pichon, Pilar, Auguste, Kurtis I., Bernardo, Danilo , Singh, Rani K., Ciliberto, Michael A., Reddy, Shilpa B., Arredondo, Kristen H. , Marashly, Ahmad , Galan, Fernando N., Armstrong, Dallas M., Wagner, Janelle L. , Wong-Kisiel, Lily C. , Bolton, Jeffrey B., Lin, Jenny, Coryell, J., Perry, Μ. Scott , Group, the rest of the PERC Surgery Special Interest, Galán, Fernando , Knox, Andrew T , Eschbach, Krista , Bernardo, Danilo , Grinspan, Zachary , Abel, Taylor J , Perry, Michael Scott , Galan, Fernando N , Wolf, Steven , McNamara, Nancy A., Novotny, Edward J. , Depositario‐Cabacar, Dewi, Karakas, Cemal , Auguste, Kurtis I. , Javarayee, Pradeep , Singh, Rani K., Ciliberto, Michael A. , Reddy, Shilpa B. , Armstrong, Dallas , Wong‐Kisiel, Lily C. , Bolton, Jeffrey , Grinspan, Zachary M. , Abel, Taylor J. , Coryell, Jason

Mayo Clinic

Epilepsia | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70440 | PMID 42621761 Get It

Abstract Objective Surgery is an effective, yet underutilized treatment for children with drug‐resistant epilepsy. Although predictors of surgical outcomes are well described, the decision to recommend surgery varies by institution. We aim to evaluate the rates of not recommending surgery, identify associated patient characteristics, and quantify variability across centers. Methods We queried the Pediatric Epilepsy Research Consortium Surgery database, a prospective multicenter cohort of children (0–18 years) undergoing initial evaluation for epilepsy surgery. Patients with documented surgical decisions were included. Demographic, clinical, and presurgical evaluation variables were compared by surgical recommendation status. Logistic regression identified factors associated with not recommending surgery. Mixed‐effects models quantified between‐center variability. Results Among 2480 patients across 29 centers, 532 (21%) were not recommended epilepsy surgery (median center rate 17%, interquartile range [IQR] 10%–28%). After accounting for patient characteristics associated with surgical candidacy, substantial variation in decision‐making remained across centers, with a median twofold difference in the odds of not recommending surgery between otherwise similar patients evaluated at different institutions (Median Odds Ratio = 2.25; Intraclass Correlation Coefficient = .18). The clinical characteristics most strongly associated with not recommending surgery included monthly or less frequent seizures (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.75–2.69), non‐structural etiology (OR 2.02, 95% CI 1.56–2.61), and taking ≤2 anti‐seizure medications (ASMs) (OR 1.67, 95% CI 1.34–2.08, all p 's < .01). These characteristics showed minimal clustering across centers (ICCs < .05). Significance One in five children evaluated for epilepsy surgery are not recommended to pursue surgical treatment. Although clinical factors influence decision‐making, they do not explain the substantial variation in recommendations across pediatric epilepsy centers. Similar children evaluated at different institutions had significant differences in the odds of not being recommended surgery, suggesting that institutional decision‐making contributes importantly to surgical candidacy.